Altimmune

Yahoo Finance • 27 days ago

Altimmune posts mid-stage trial data showing antifibrotic activity of lead asset in MASH

[Human Internal Digestive Organ Liver Anatomy] magicmine/iStock via Getty Images Altimmune (ALT [https://seekingalpha.com/symbol/ALT]) on Friday announced initial results from a mid-stage trial for its lead asset pemvidutide in metabolic... Full story

Yahoo Finance • 27 days ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorabl... Full story

Yahoo Finance • last month

Altimmune CEO Vipin Garg To Step Down; Stock Down In Pre-Market

(RTTNews) - Altimmune, Inc.(ALT), a developer of novel peptide-based therapeutics for liver and metabolic diseases, said on Monday that its Chief Executive Officer, Vipin Garg, will step down with effect from January 1, 2026. Subsequently... Full story

Yahoo Finance • last month

Altimmune Announces CEO Transition and Succession Plan

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Na... Full story

Yahoo Finance • 2 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 2 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-in... Full story

Yahoo Finance • 2 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 3 months ago

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

By Bhanvi Satija LONDON (Reuters) -Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its pipeline of experi... Full story

Yahoo Finance • 3 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that... Full story

Yahoo Finance • 3 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clini... Full story

Yahoo Finance • 3 months ago

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT): Grabar Law Office is investigating claims on behalf of shareholders of Altimmune, Inc. (NASDAQ: ALT). The investigation concerns whether certain officers an... Full story

Yahoo Finance • 3 months ago

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Altimmune between August 10,... Full story

Yahoo Finance • 3 months ago

Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALT

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 3 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August... Full story

Yahoo Finance • 3 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between Aug... Full story

Yahoo Finance • 3 months ago

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune”... Full story

Yahoo Finance • 3 months ago

ALT FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important October 6 Deadline in Securities Class Action – ALT

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the... Full story

Yahoo Finance • 3 months ago

ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of October 6th Deadline and Urges Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Altimmune (ALT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August... Full story

Yahoo Finance • 3 months ago

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover lo... Full story

Yahoo Finance • 4 months ago

ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 6 Deadline in Securities Class Action - ALT

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of th... Full story